Biocon Ltd. is set to seek regulatory approvals for generic versions of Novo Nordisk's Ozempic and Wegovy, targeting key markets like Canad...

Biocon has secured Indian regulatory approval for its generic Liraglutide drug substance and product, a version of Victoza, for treating Ty...

Biocon shares are in focus as the company has received regulatory approval from the Central Drugs Standard Control Organisation for its dia...

Novo will pay Hong Kong-based United Laboratories $200 million upfront for the drug, which combines three different mechanisms in an effort...

Biocon Ltd and Zentiva have secured decentralised procedure approval in the EU for Liraglutide, a complex formulation used for diabetes and...

U.S. health insurance claims analysis shows that two years after starting Novo Nordisk's Wegovy or similar GLP-1 drugs, annual medical cost...

New data suggests that semaglutide may also cut the risk of stroke or heart attack, and may delay the progression of kidney disease in diab...

In a statement, the Hyderabad-based company that reported Rs 15 crore of revenue last fiscal year, said it would soon take up clinical stud...

"India has a high incidence of non-communicable diseases, especially diabetes, and it is mostly because it is poorly regulated," said Søren...

The once-a-week non-insulin injectable Trulicity is distinct in the duration of dosage compared to products like Novo Nordisk's Victoza or ...

The move will drastically reduce prices of key drugs, but at the same time, jeopardise the plans of multinational drug companies.

Denmark's Novo Nordisk said it would launch its potential blockbuster drug Victoza in Japan this month.